View in EDS HTML Full Text PDF Full Text

Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.

Saved in:
Bibliographic Details
Title: Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Authors: Brose MS; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Now at Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia, PA, USA., Robinson BG; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Vaisman F; Endocrinology Service, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Hoff AO; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Hitre E; Department of Medical Oncology and Clinical Pharmacology 'B', Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA., Sen S; Exelixis, Inc., Alameda, California, USA., Oliver JW; Exelixis, Inc., Alameda, California, USA., Banerjee K; Exelixis, Inc., Alameda, California, USA., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Capdevila J; Medical Oncology Department Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Source: Cancer [Cancer] 2022 Dec 15; Vol. 128 (24), pp. 4203-4212. Date of Electronic Publication: 2022 Oct 19.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36259380
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brose+MS%22">Brose MS</searchLink>; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Now at Sidney Kimmel Cancer Center, Jefferson Health, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Robinson+BG%22">Robinson BG</searchLink>; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Sherman+SI%22">Sherman SI</searchLink>; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.<br /><searchLink fieldCode="AU" term="%22Jarzab+B%22">Jarzab B</searchLink>; Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska Curie National Research Institute of Oncology, Gliwice, Poland.<br /><searchLink fieldCode="AU" term="%22Lin+CC%22">Lin CC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Vaisman+F%22">Vaisman F</searchLink>; Endocrinology Service, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Hoff+AO%22">Hoff AO</searchLink>; Department of Endocrinology, Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Hitre+E%22">Hitre E</searchLink>; Department of Medical Oncology and Clinical Pharmacology 'B', Országos Onkológiai Intézet, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Bowles+DW%22">Bowles DW</searchLink>; Division of Medical Oncology, Department of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, Colorado, USA.<br /><searchLink fieldCode="AU" term="%22Sen+S%22">Sen S</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Oliver+JW%22">Oliver JW</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Banerjee+K%22">Banerjee K</searchLink>; Exelixis, Inc., Alameda, California, USA.<br /><searchLink fieldCode="AU" term="%22Keam+B%22">Keam B</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Capdevila+J%22">Capdevila J</searchLink>; Medical Oncology Department Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2022 Dec 15; Vol. 128 (24), pp. 4203-4212. <i>Date of Electronic Publication: </i>2022 Oct 19.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36259380
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/cncr.34493
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 4203
    Titles:
      – TitleFull: Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brose MS
      – PersonEntity:
          Name:
            NameFull: Robinson BG
      – PersonEntity:
          Name:
            NameFull: Sherman SI
      – PersonEntity:
          Name:
            NameFull: Jarzab B
      – PersonEntity:
          Name:
            NameFull: Lin CC
      – PersonEntity:
          Name:
            NameFull: Vaisman F
      – PersonEntity:
          Name:
            NameFull: Hoff AO
      – PersonEntity:
          Name:
            NameFull: Hitre E
      – PersonEntity:
          Name:
            NameFull: Bowles DW
      – PersonEntity:
          Name:
            NameFull: Sen S
      – PersonEntity:
          Name:
            NameFull: Oliver JW
      – PersonEntity:
          Name:
            NameFull: Banerjee K
      – PersonEntity:
          Name:
            NameFull: Keam B
      – PersonEntity:
          Name:
            NameFull: Capdevila J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 12
              Text: 2022 Dec 15
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1097-0142
          Numbering:
            – Type: volume
              Value: 128
            – Type: issue
              Value: 24
          Titles:
            – TitleFull: Cancer
              Type: main
ResultId 1